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Rapamycin/Sirolimus™ leads to the regression of trans-
plant-associated Kaposi sarcoma (KS). It also leads to
disease stabilization in HIV-associated KS. Case reports
and a wealth of preclinical studies support rapamycin’s
efficacy also in AIDS associated lymphoma, such as pri-
mary effusion lymphoma (PEL). Rapamycin inhibits the
mammalian target of rapamycin (mTOR) and papamy-
cin derivatives are approved for the treatment of mantle
cell lymphoma and other cancers. It is not universally
effective against all solid tumors. Even within this group
of clinically responsive cancers, there are exceptions of
cases or cell models in which this drug or its derivatives
(rapalogs) fail.
We hypothesized that genetic alterations of the tumor
will determine the response to rapalogs. We used a novel
KS TMA (from the AIDS cancer specimen resource
(ACSR) to evaluate the PI3K/Akt/mTOR pathway in KS
and identified a unique pattern of protein activation that is
associated with sustained expression and phosphorylation
of the PTEN tumor suppressor protein. We used Affyme-
trix array-based comparative genome hybridization (CGH)
and targeted sequencing to query genomic loci of mem-
bers of the mTOR pathway, which confirmed the absence
of genetic alterations, which in other cancers have been
associated with mTOR pathway activation. We conclude
that in KS, PEL and perhaps other virus-associated cancer
the mTOR pathway is activated post-translationally, which
is not as permanent and does not have the same impact as
for instance a deletion in PTEN. This may explain the
unique sensitivity of these tumor types to rapalogs.
We established a novel animal model of KS (L1T2
cells), which develops tumors with short latency and in
which the KS associated herpesvirus (KSHV) is main-
tained in each tumor cell. We evaluated multiple rapa-
logs (Sirolimus™,T e m s i r o l i m u s ™,E v e r o l i m u s ™),
Tacrolimus/FK506 and Doxil™ in this model. We found
sustained, but reversible tumor suppression by the rapa-
logs, which was associated (a) with inhibition of mTOR
activity and (b) with reduced neo-angiogensis. In this
model rapalogs outperformed Doxil™,p r e s u m a b l y
because of a combined effect on endothelial lineage KS
tumor cells and endothelia lineage tumor vasculature.
This represents the first animal test of rapalogs in a
human KS tumor model, it validates novel biomarkers
and provides a strong rational for further clinical devel-
opment and testing of rapalogs in AIDS-associated
Kaposi sarcoma.
As rapamycin has recently become affordable and is
available in developing countries, where the majority of
KS-associated mortality occurs, it is one of the few new
anti-cancer drugs with a cost/benefit profile that is
affordable for global cancer treatment.
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